News

One year of treatment with Genentech‘s Esbriet (pirfenidone) significantly reduced the incidence of disease progression events — including decline in lung function and physical capacity, respiratory-related hospitalizations, and death — in people with idiopathic pulmonary fibrosis…

A Phase 1 trial shows that combining Sprycel (dasatinib) with the plant-based flavonoid quercetin improved the physical function of people with idiopathic pulmonary fibrosis (IPF). However, patients’ pulmonary function remained unchanged. The study, “Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study” was published…

A Phase 1 trial of an investigational treatment for idiopathic pulmonary fibrosis (IPF), PLN-74809, has dosed a first group of healthy participants, Pliant Therapeutics announced. PLN-74809,  the company’s lead candidate, is a small molecule that selectively inhibits both alphaVβ1 and αVβ6 integrins. These proteins mediate cell adhesion and are specific for…

Promedior plans to begin Phase 3 testing of its investigational therapy PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF), now that the U.S. Food and Drug Administration has signed off on the trial design, the biotechnology company announced. The agreement was reached in an end-of-Phase-2 meeting between…

Galapagos has started the worldwide ISABELA Phase 3 program to evaluate the potential of GLPG1690 as a treatment for idiopathic pulmonary fibrosis (IPF), reporting that the first participant has already been treated. GLPG1690 inhibits autotaxin, an enzyme that is thought to be involved in tissue scarring (fibrosis) and…

Researchers from the Medical University of South Carolina (MUSC) may have found a new therapeutic target for the treatment of pulmonary fibrosis using a preclinical model of the disease. The candidate protein, called insulin-like growth factor-binding protein 5 (IGFBP-5), induces lung fibrosis (scarring) early on by turning on genes…

Throughout 2018, Pulmonary Fibrosis News provided you daily coverage of key discoveries, potential treatments, and clinical trials related to pulmonary fibrosis (PF). As we look forward to bringing more news to patients, family members, and caregivers dealing with PF in 2019, here are the Top 10 most-read articles of 2018,…

When Kim Fredrickson was diagnosed with pulmonary fibrosis (PF) four and a half years ago, she was a self-described mess. She had a disease she had never heard of, and a doctor who didn’t explain it. So naturally, she turned to the internet. She was not consoled. “I…

A study found a link between MUC5B-induced mucus accumulation and the progression of idiopathic pulmonary fibrosis, reporting that a MUC5B mutation can prevent mucus clearance in the small airways and induce scarring, indicating a strong risk factor in IPF. The study, “Muc5b overexpression causes mucociliary dysfunction and enhances…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…